Gliosarcoma - Pipeline Review, H2 2016

Published: Nov, 2016 | Pages: 141 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gliosarcoma - Pipeline Review, H2 2016, provides an overview of the Gliosarcoma (Oncology) pipeline landscape.

Gliosarcoma is a type of brain tumor that originates from glial cells. The tumor grows rapidly and symptom will vary depending on the exact location and size of the tumor. Most likely they may be headache, vomiting, cognitive problems, and drowsiness. Treatment of brain tumors depends upon the type and staging of the tumor, its size and position in the brain, as well as the age and other health problems of patient.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gliosarcoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Gliosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gliosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gliosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 12, 7 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.Gliosarcoma.

Gliosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Gliosarcoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Gliosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gliosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Gliosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Gliosarcoma (Oncology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gliosarcoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Gliosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6

Introduction 7
Global Markets Direct Report Coverage 7
Gliosarcoma Overview 8
Therapeutics Development 9
Pipeline Products for Gliosarcoma - Overview 9
Pipeline Products for Gliosarcoma - Comparative Analysis 10
Gliosarcoma - Therapeutics under Development by Companies 11
Gliosarcoma - Therapeutics under Investigation by Universities/Institutes 13
Gliosarcoma - Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Gliosarcoma - Products under Development by Companies 16
Gliosarcoma - Products under Investigation by Universities/Institutes 17
Gliosarcoma - Companies Involved in Therapeutics Development 18
Amgen Inc. 18
Axelar AB 19
Bristol-Myers Squibb Company 20
Burzynski Research Institute, Inc. 21
Celgene Corporation 22
Cortice Biosciences, Inc. 23
ERC Belgium SA 24
Merck & Co., Inc. 25
Millennium Pharmaceuticals Inc 26
NewLink Genetics Corporation 27
Novartis AG 28
Nuo Therapeutics, Inc. 29
Progenics Pharmaceuticals, Inc. 30
Triphase Accelerator Corporation 31
Gliosarcoma - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Combination Products 33
Assessment by Target 34
Assessment by Mechanism of Action 37
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 44
ALD-451 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
alisertib - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Antineoplaston Therapy - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
AXL-1717 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
CC-122 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
dasatinib - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
DNX-2401 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
ERC-1671 - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
flucytosine + TBio-01 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
indoximod - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
irinotecan hydrochloride + TBio-02 - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
lonafarnib - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
M-032 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
marizomib - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
p28 - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
pazopanib hydrochloride - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
pembrolizumab - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
PSMA ADC - Drug Profile 124
Product Description 124
Mechanism Of Action 124
R&D Progress 124
rilotumumab - Drug Profile 128
Product Description 128
Mechanism Of Action 128
R&D Progress 128
RRX-001 - Drug Profile 130
Product Description 130
Mechanism Of Action 130
R&D Progress 130
TPI-287 - Drug Profile 132
Product Description 132
Mechanism Of Action 132
R&D Progress 132
urelumab - Drug Profile 136
Product Description 136
Mechanism Of Action 136
R&D Progress 136
Gliosarcoma - Dormant Projects 138
Gliosarcoma - Product Development Milestones 139
Featured News & Press Releases 139
Nov 26, 2013: Burzynski Clinic Presents the Successful Treatment of a Child with Recurrent Diffuse Intrinsic Pontine Gliosarcoma at the Congress 139

Appendix 140
Methodology 140
Coverage 140
Secondary Research 140
Primary Research 140
Expert Panel Validation 140
Contact Us 140
Disclaimer 141

List of Tables

Number of Products under Development for Gliosarcoma, H2 2016 9
Number of Products under Development for Gliosarcoma - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 12
Number of Products under Investigation by Universities/Institutes, H2 2016 13
Comparative Analysis by Clinical Stage Development, H2 2016 14
Comparative Analysis by Early Stage Development, H2 2016 15
Products under Development by Companies, H2 2016 16
Products under Investigation by Universities/Institutes, H2 2016 17
Gliosarcoma - Pipeline by Amgen Inc., H2 2016 18
Gliosarcoma - Pipeline by Axelar AB, H2 2016 19
Gliosarcoma - Pipeline by Bristol-Myers Squibb Company, H2 2016 20
Gliosarcoma - Pipeline by Burzynski Research Institute, Inc., H2 2016 21
Gliosarcoma - Pipeline by Celgene Corporation, H2 2016 22
Gliosarcoma - Pipeline by Cortice Biosciences, Inc., H2 2016 23
Gliosarcoma - Pipeline by ERC Belgium SA, H2 2016 24
Gliosarcoma - Pipeline by Merck & Co., Inc., H2 2016 25
Gliosarcoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 26
Gliosarcoma - Pipeline by NewLink Genetics Corporation, H2 2016 27
Gliosarcoma - Pipeline by Novartis AG, H2 2016 28
Gliosarcoma - Pipeline by Nuo Therapeutics, Inc., H2 2016 29
Gliosarcoma - Pipeline by Progenics Pharmaceuticals, Inc., H2 2016 30
Gliosarcoma - Pipeline by Triphase Accelerator Corporation, H2 2016 31
Assessment by Monotherapy Products, H2 2016 32
Assessment by Combination Products, H2 2016 33
Number of Products by Stage and Target, H2 2016 35
Number of Products by Stage and Mechanism of Action, H2 2016 38
Number of Products by Stage and Route of Administration, H2 2016 41
Number of Products by Stage and Molecule Type, H2 2016 43
Gliosarcoma - Dormant Projects, H2 2016 138